Soleno Therapeutics Inc

Research Soleno Therapeutics Inc (SLNO) on Bullrun: market cap USD 2.76B, P/E 30.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSLNO
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.76B
• P/E30.1
• Financial periodQ1 2026
• RevenueUSD 285.01M
• Net incomeUSD 31.38M
• Free cash flowUSD 105.42M
• Gross margin32.8%

Valuation Snapshot

latest market cap is USD 2.76B; P/E is 30.1.

About Soleno Therapeutics Inc

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Frequently asked questions

What is Soleno Therapeutics Inc's market cap?

Soleno Therapeutics Inc's market capitalization is USD 2.76B.

What is Soleno Therapeutics Inc's P/E ratio?

Soleno Therapeutics Inc's price-to-earnings (P/E) ratio is 30.1.

What does Soleno Therapeutics Inc do?

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome.